Indivior (NASDAQ:INDV) Rating Increased to Strong-Buy at RODMAN&RENSHAW

Indivior (NASDAQ:INDV) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other equities research analysts have also commented on the company. Rodman & Renshaw initiated coverage on Indivior in a research note on Tuesday. They set a “buy” rating and a $16.00 price target for the company. Craig Hallum dropped their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Stock Up 1.7 %

Shares of NASDAQ INDV opened at $12.22 on Tuesday. The stock has a market capitalization of $1.68 billion, a PE ratio of -305.42 and a beta of 0.74. The firm has a fifty day moving average of $11.72 and a 200-day moving average of $11.01. Indivior has a 52-week low of $7.33 and a 52-week high of $23.22.

Hedge Funds Weigh In On Indivior

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior during the 4th quarter valued at approximately $56,000. Stifel Financial Corp bought a new stake in shares of Indivior in the third quarter worth $100,000. Melqart Asset Management UK Ltd acquired a new stake in Indivior in the third quarter valued at $132,000. Jane Street Group LLC bought a new position in Indivior during the 3rd quarter valued at $180,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Indivior during the 3rd quarter worth $294,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.